Back to Journals » Vascular Health and Risk Management » Volume 5

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia

Authors Johansen O, Vanberg P, Kilhovd B, Palmstrøm Jørgensen A

Published 18 December 2008 Volume 2009:5 Pages 121—128


Review by Single-blind

Peer reviewer comments 2

Odd Erik Johansen1, Pål Johan Vanberg1, Bente Kvarv Kilhovd2, Anders Palmstrøm Jørgensen1

1Medical Department, Asker and Baerum Hospital, RUD, Norway; 2Department of Endocrinology, Aker University Hospital, OSLO, Norway

Background: The insulin analogs, glargine and detemir, are associated with reduced hypoglycemia incidence compared with NPH insulin. We assessed the impact of changing basal insulin from NPH to glargine or detemir in patients with type 1 diabetes mellitus who experienced severe hypoglycemia.

Material and methods: A retrospective chart review was conducted that included 73 (31 female) patients (mean age 48 years, diabetes duration 19 years) treated for 12 to 24 months with insulin glargine (n = 43) or detemir (n = 30).

Results: There were no patients who withdrew from treatment due to side effects. The mean treatment duration in both groups was 18 months. Changing from NPH insulin was associated with a −0.3% (p = 0.036) reduction in HbA1c for glargine (baseline 8.8%) and −0.4% (p = 0.040) for detemir (baseline 8.3%) treated patients; insulin dosages increased, respectively by 4.1 (p = 0.045) and 4.3 units (p = 0.004) (mean values). Weight did not increase significantly and the 1-year rate of serious hypoglycemia was 0.25/person/year.

Conclusion: Switching from NPH-insulin to insulin detemir or glargine in type 1 diabetes mellitus patients with previous serious hypoglycemia was associated with a reduction in HbA1c. However, severe hypoglycemia was not completely eliminated, and few patients reached internationally accepted glycemic treatment goals.

Literature search: We searched Medline, PubMed (with key search terms type 1 diabetes, NPH insulin, detemir, glargine and serious hypoglycemia), reference lists and databases of ongoing and completed trials (through July 2008) provided from the manufacturers of the drugs to identify relevant literature.

Keywords: type 1 diabetes mellitus, insulin, observational study, HbA1c, efficacy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Readers of this article also read:

Euthanasia and assisted suicide: a physician’s and ethicist’s perspectives [Corrigendum]

Boudreau JD, Somerville MA

Medicolegal and Bioethics 2014, 4:13-14

Published Date: 11 September 2014

Fabrication of nanoadjuvant with poly-ɛ-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity [Corrigendum]

Prashant CK, Bhat M, Srivastava SK, Saxena A, Kumar M, Singh A, Samim M, Ahmad FJ, Dinda AK

International Journal of Nanomedicine 2014, 9:4033-4034

Published Date: 21 August 2014

Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016)

Ueno T, Endo K, Hori K, Ozaki N, Tsuji A, Kondo S, Wakisaka N, Murono S, Kataoka K, Kato Y, Yoshizaki T

International Journal of Nanomedicine 2014, 9:3005-3012

Published Date: 19 June 2014

Comorbidity and survival of Danish ovarian cancer patients from 2000–2011: a population-based cohort study

Grann AF, Thomsen RW, Jacobsen JB, Nørgaard M, Blaakaer J, Søgaard M

Clinical Epidemiology 2013, 5:57-63

Published Date: 1 November 2013

Causal diagrams and the cross-sectional study

Shahar E, Shahar DJ

Clinical Epidemiology 2013, 5:57-65

Published Date: 9 March 2013


Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:49-50

Published Date: 20 December 2012

Prasugrel for the treatment of patients with acute coronary syndrome

Filippo Marzot, Vittorio Pengo

Vascular Health and Risk Management 2009, 5:321-324

Published Date: 6 April 2009

Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization

Clarissa Cola, Salvatore Brugaletta, Victoria Martín Yuste, Bieito Campos, Dominick J Angiolillo, Manel Sabaté

Vascular Health and Risk Management 2009, 5:101-119

Published Date: 11 January 2009